Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AN ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY OLDER ADULTS

Trial Profile

A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AN ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY OLDER ADULTS

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Respiratory syncytial virus vaccine (Primary) ; Influenza virus vaccine
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Feb 2019 Planned number of patients changed from 474 to 312.
    • 05 Feb 2019 Planned End Date changed from 30 Jun 2020 to 29 Jun 2020.
    • 05 Feb 2019 Planned primary completion date changed from 30 Jun 2020 to 29 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top